Hexagon Bio Secures $62M Series C to Accelerate ADC Payload Platform

Biotech firm Hexagon Bio raises $62 million in a Series C led by The Column Group to speed up antibody-drug conjugate payload discovery.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here